JP2022522873A5 - - Google Patents
Info
- Publication number
- JP2022522873A5 JP2022522873A5 JP2021552515A JP2021552515A JP2022522873A5 JP 2022522873 A5 JP2022522873 A5 JP 2022522873A5 JP 2021552515 A JP2021552515 A JP 2021552515A JP 2021552515 A JP2021552515 A JP 2021552515A JP 2022522873 A5 JP2022522873 A5 JP 2022522873A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- dose
- administered
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024180821A JP7801408B2 (ja) | 2019-03-04 | 2024-10-16 | レボケトコナゾールによる疾患の処置方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813399P | 2019-03-04 | 2019-03-04 | |
| US62/813,399 | 2019-03-04 | ||
| PCT/US2020/020644 WO2020180784A1 (en) | 2019-03-04 | 2020-03-02 | Methods of treating disease with levoketoconazole |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024180821A Division JP7801408B2 (ja) | 2019-03-04 | 2024-10-16 | レボケトコナゾールによる疾患の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522873A JP2022522873A (ja) | 2022-04-20 |
| JP2022522873A5 true JP2022522873A5 (https=) | 2023-03-09 |
| JP7574204B2 JP7574204B2 (ja) | 2024-10-28 |
Family
ID=72338256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552515A Active JP7574204B2 (ja) | 2019-03-04 | 2020-03-02 | レボケトコナゾールによる疾患の処置方法 |
| JP2024180821A Active JP7801408B2 (ja) | 2019-03-04 | 2024-10-16 | レボケトコナゾールによる疾患の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024180821A Active JP7801408B2 (ja) | 2019-03-04 | 2024-10-16 | レボケトコナゾールによる疾患の処置方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11020393B2 (https=) |
| EP (1) | EP3934649A4 (https=) |
| JP (2) | JP7574204B2 (https=) |
| KR (2) | KR102950333B1 (https=) |
| CN (1) | CN113710250A (https=) |
| AU (2) | AU2020232246B2 (https=) |
| BR (1) | BR112021017561A2 (https=) |
| CA (1) | CA3132319A1 (https=) |
| IL (1) | IL286099A (https=) |
| WO (1) | WO2020180784A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7574204B2 (ja) * | 2019-03-04 | 2024-10-28 | ストロングブリッジ ダブリン リミテッド | レボケトコナゾールによる疾患の処置方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006204334B2 (en) * | 2005-01-10 | 2012-02-23 | Cortendo Ab (Publ) | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
| AU2007303219A1 (en) * | 2006-10-02 | 2008-04-10 | Cortendo Ab (Publ) | Ketoconazole enantiomer in humans |
| TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| US11261157B2 (en) * | 2016-12-08 | 2022-03-01 | Novatarg, Inc. | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy |
| US10512667B2 (en) * | 2017-06-27 | 2019-12-24 | The Regents Of The University Of Michigan | Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production |
| JP7574204B2 (ja) * | 2019-03-04 | 2024-10-28 | ストロングブリッジ ダブリン リミテッド | レボケトコナゾールによる疾患の処置方法 |
-
2020
- 2020-03-02 JP JP2021552515A patent/JP7574204B2/ja active Active
- 2020-03-02 KR KR1020217031645A patent/KR102950333B1/ko active Active
- 2020-03-02 KR KR1020267010641A patent/KR20260049881A/ko active Pending
- 2020-03-02 WO PCT/US2020/020644 patent/WO2020180784A1/en not_active Ceased
- 2020-03-02 CN CN202080029583.4A patent/CN113710250A/zh active Pending
- 2020-03-02 BR BR112021017561A patent/BR112021017561A2/pt unknown
- 2020-03-02 CA CA3132319A patent/CA3132319A1/en active Pending
- 2020-03-02 AU AU2020232246A patent/AU2020232246B2/en active Active
- 2020-03-02 EP EP20766266.9A patent/EP3934649A4/en active Pending
- 2020-09-02 US US17/010,387 patent/US11020393B2/en active Active
-
2021
- 2021-05-13 US US17/319,781 patent/US11278547B2/en active Active
- 2021-09-02 IL IL286099A patent/IL286099A/en unknown
-
2022
- 2022-03-21 US US17/655,632 patent/US11903940B2/en active Active
-
2024
- 2024-01-16 US US18/414,250 patent/US12377096B2/en active Active
- 2024-10-16 JP JP2024180821A patent/JP7801408B2/ja active Active
-
2025
- 2025-06-12 AU AU2025204382A patent/AU2025204382A1/en active Pending
- 2025-07-02 US US19/257,990 patent/US20250387389A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052458A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| JP2018184417A5 (https=) | ||
| JP2023088944A5 (https=) | ||
| JP2022510410A5 (https=) | ||
| JP2022537551A5 (https=) | ||
| JP2017535547A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| JP2019501886A5 (https=) | ||
| JP2020516646A5 (https=) | ||
| JP2015525798A5 (https=) | ||
| JP2024527109A5 (https=) | ||
| JP2021535161A5 (https=) | ||
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP2023540795A5 (https=) | ||
| JP2022505041A5 (https=) | ||
| Takeuchi et al. | OP0040 adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (Surprise Study) | |
| JP2024016209A5 (https=) | ||
| JPWO2020250915A5 (https=) | ||
| JP2022547452A5 (https=) | ||
| AU2021255084B2 (en) | Breast cancer therapeutic agent | |
| JP2022546456A5 (https=) | ||
| JP2022522873A5 (https=) | ||
| JP2024517085A5 (https=) |